William Blair Investment Management LLC Grows Stock Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

William Blair Investment Management LLC grew its position in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 2.5% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 380,324 shares of the medical equipment provider’s stock after acquiring an additional 9,245 shares during the quarter. William Blair Investment Management LLC owned about 0.55% of Lantheus worth $34,024,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in LNTH. State of New Jersey Common Pension Fund D increased its stake in Lantheus by 0.4% during the fourth quarter. State of New Jersey Common Pension Fund D now owns 26,428 shares of the medical equipment provider’s stock worth $2,364,000 after acquiring an additional 115 shares during the last quarter. Bleakley Financial Group LLC increased its stake in Lantheus by 6.1% during the fourth quarter. Bleakley Financial Group LLC now owns 2,237 shares of the medical equipment provider’s stock worth $200,000 after acquiring an additional 129 shares during the last quarter. Avantax Advisory Services Inc. increased its stake in Lantheus by 5.9% during the fourth quarter. Avantax Advisory Services Inc. now owns 2,382 shares of the medical equipment provider’s stock worth $213,000 after acquiring an additional 132 shares during the last quarter. UMB Bank n.a. increased its stake in Lantheus by 31.5% during the fourth quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider’s stock worth $50,000 after acquiring an additional 134 shares during the last quarter. Finally, Aurora Investment Counsel increased its stake in Lantheus by 0.8% during the fourth quarter. Aurora Investment Counsel now owns 19,200 shares of the medical equipment provider’s stock worth $1,718,000 after acquiring an additional 146 shares during the last quarter. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Insider Activity at Lantheus

In other Lantheus news, Director Mary Anne Heino sold 53,107 shares of the stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $94.35, for a total transaction of $5,010,645.45. Following the transaction, the director now owns 440,399 shares of the company’s stock, valued at $41,551,645.65. This represents a 10.76 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, Director James H. Thrall sold 1,000 shares of the stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total value of $94,760.00. Following the transaction, the director now directly owns 33,207 shares in the company, valued at approximately $3,146,695.32. This represents a 2.92 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 54,109 shares of company stock valued at $5,105,606. 1.50% of the stock is owned by corporate insiders.

Analyst Ratings Changes

LNTH has been the subject of several recent analyst reports. JMP Securities reissued a “market outperform” rating and set a $112.00 target price on shares of Lantheus in a research note on Tuesday, January 14th. Truist Financial lifted their price objective on Lantheus from $120.00 to $127.00 and gave the company a “buy” rating in a research note on Thursday, February 27th. StockNews.com cut Lantheus from a “buy” rating to a “hold” rating in a research note on Thursday, November 21st. Finally, The Goldman Sachs Group began coverage on Lantheus in a research note on Wednesday, December 18th. They issued a “buy” rating and a $143.00 price objective for the company. One analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $132.86.

Lantheus Price Performance

LNTH opened at $102.22 on Wednesday. The stock has a market cap of $7.00 billion, a P/E ratio of 17.01 and a beta of 0.38. The stock’s 50 day simple moving average is $92.35 and its 200 day simple moving average is $96.64. Lantheus Holdings, Inc. has a 1-year low of $56.52 and a 1-year high of $126.89.

Lantheus (NASDAQ:LNTH) last released its quarterly earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share for the quarter, missing analysts’ consensus estimates of $1.57 by ($0.23). The firm had revenue of $391.11 million during the quarter, compared to analyst estimates of $376.61 million. Lantheus had a return on equity of 44.29% and a net margin of 28.57%. Research analysts expect that Lantheus Holdings, Inc. will post 6.01 EPS for the current fiscal year.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.